Mohamad Taleuzzaman | Pharmacology | Best Researcher Award

Published on by Forensic Scientist

Prof. Dr. Mohamad Taleuzzaman | Pharmacology | Best Researcher Award

Maulana Azad University | India

Dr. Mohamad Taleuzzaman is a distinguished academician and researcher in the field of pharmaceutical chemistry. With a career spanning over 15 years, he has contributed significantly to pharmaceutical education, research, and administration. Currently serving as a Professor and Head of the Department at Maulana Azad University, Jodhpur, his expertise lies in pharmaceutical analysis, drug development, and bioanalytical research. Passionate about scientific innovation, he has played a vital role in mentoring students and advancing pharmaceutical sciences.

Professional profile👤

Google Scholar

ORCID

Scopus

Strengths for the Awards✨

  • Extensive Research Contributions – Dr. Taleuzzaman has numerous publications in high-impact journals, showcasing his active engagement in research.

  • Diverse Research Interests – His work spans pharmaceutical chemistry, nanotechnology, molecular docking, and bioanalytical method development.

  • Academic Leadership – Serving as a Professor and HOD, he has contributed to institutional development and research coordination.

  • Patent Holder – His patent on a polymeric nano scaffold for anti-diabetic applications highlights his innovation.

  • Mentorship – He has successfully guided Ph.D. and M.Pharm students, contributing to academic growth.

  • Strong Administrative Experience – Coordinating academic inspections, examinations, and regulatory compliance.

Education 🎓

Dr. Taleuzzaman pursued his Ph.D. in Pharmaceutical Chemistry from Glocal University, Saharanpur, in 2018. He completed his M.Pharm in Pharmaceutical Analysis from Jamia Hamdard, New Delhi, securing a first-class distinction with 73.84% in 2007. His academic journey began with a B.Pharm from the same institution in 2005. Additionally, he qualified for the GATE examination in 2005 with an impressive percentile of 92.49, further solidifying his strong foundation in pharmaceutical sciences.

Professional Experience 💼

With over 15 years of professional experience, Dr. Taleuzzaman has held key positions in both academia and the pharmaceutical industry. Since 2019, he has been serving as a Professor and HOD at Maulana Azad University, Jodhpur. Prior to this, he worked as an Associate Professor at Glocal School of Pharmacy, Saharanpur, and as an Assistant Professor at KIET School of Pharmacy, Ghaziabad. His industrial experience includes roles such as Product Development Manager at Ultra Biolabs Pvt. Ltd., Chandigarh, and Quality Officer at Ali & Abdul Karim Trading Co., Oman.

Research Interests On Pharmacology 📚

Dr. Taleuzzaman’s research is centered on pharmaceutical analysis, drug formulation, and bioanalytical method development. His Ph.D. research focused on the extraction, characterization, and quantification of thymoquinone and eugenol from Nigella sativa and Myristica fragrans. He has also explored novel drug delivery systems, nanotechnology applications in pharmaceuticals, and synthetic methodologies for bioactive compounds.

Awards & Recognitions 🏆

Dr. Taleuzzaman has been recognized for his contributions to pharmaceutical sciences and academic excellence. His innovative research has led to a patent titled “Sitagliptin loaded polymeric nano scaffold for enhanced anti-diabetic performance” (Patent number: 2021104076). He has also been actively involved in coordinating major academic accreditations such as PCI, UGC, and NAAC inspections at leading pharmacy institutions.

Publications 📄

Dr. Taleuzzaman has published extensively in high-impact journals. Some of his notable research articles include:

  • Ultra performance liquid chromatography (UPLC)-a review
    Authors: M Taleuzzaman, S Ali, SJ Gilani, SS Imam, A Hafeez
    Year: 2015
    Citations: 133

  • Limit of blank (LOB), limit of detection (LOD), and limit of quantification (LOQ)
    Author: M Taleuzzaman
    Year: 2018
    Citations: 88

  • Eugenol as a potential drug candidate: A review
    Authors: M Taleuzzaman, P Jain, R Verma, Z Iqbal, MA Mirza
    Year: 2021
    Citations: 79

  • Clarithromycin-loaded ocular chitosan nanoparticle: formulation, optimization, characterization, ocular irritation, and antimicrobial activity
    Authors: M Bin-Jumah, SJ Gilani, MA Jahangir, A Zafar, S Alshehri, M Yasir, C Kala, …
    Year: 2020
    Citations: 70

  • Quality by design (Qbd) assisted development of phytosomal gel of aloe vera extract for topical delivery
    Authors: P Jain, M Taleuzzaman, C Kala, D Kumar Gupta, A Ali, M Aslam
    Year: 2021
    Citations: 48

  • Nano phytomedicine based delivery system for CNS disease
    Authors: MA Jahangir, C Anand, A Muheem, SJ Gilani, M Taleuzzaman, A Zafar, …
    Year: 2020
    Citations: 44

  • Thymoquinone-entrapped chitosan-modified nanoparticles: formulation optimization to preclinical bioavailability assessments
    Authors: I Rahat, SS Imam, M Rizwanullah, S Alshehri, M Asif, C Kala, …
    Year: 2021
    Citations: 36

  • Benzothiazole incorporated thiazolidin-4-ones and azetidin-2-ones derivatives: Synthesis and in vitro antimicrobial evaluation
    Authors: SJ Gilani, K Nagarajan, SP Dixit, M Taleuzzaman, SA Khan
    Year: 2016
    Citations: 30

  • Phytosomal gel of Manjistha extract (MJE) formulated and optimized with central composite design of Quality by Design (QbD)
    Authors: M Taleuzzaman, A Sartaj, D Kumar Gupta, SJ Gilani, MA Mirza
    Year: 2023
    Citations: 29

  • Formulation and evaluation of thymoquinone niosomes: Application of developed and validated RP-HPLC method in delivery system
    Authors: SJ Gilani, SS Imam, A Ahmed, S Chauhan, MA Mirza, M Taleuzzaman
    Year: 2019
    Citations: 28

Conclusion 🔗

Dr. Mohamad Taleuzzaman’s dedication to pharmaceutical research and education has made a profound impact on the field. His work in drug development, bioanalytical chemistry, and nanotechnology has contributed to the advancement of pharmaceutical sciences. As a mentor, researcher, and academic leader, he continues to inspire and shape the future of pharmaceutical research.

Shanbo Ma | Pharmacology | Best Researcher Award

Published on by Forensic Scientist

Dr. Shanbo Ma | Pharmacology | Best Researcher Award

Deputy Chief Pharmacist | Xijing Hospital of Air Force Medical University | China

Shanbo Ma is a dedicated researcher in the field of Chinese pharmacology, focusing on the pharmacological mechanisms and therapeutic potential of traditional Chinese medicine (TCM). With a strong academic background and extensive research experience, he has contributed significantly to the study of anti-inflammatory effects and active ingredients in TCM. His expertise spans molecular biology, cell biology, and bioinformatics, making him a key figure in integrating computational and experimental approaches to drug discovery.

Professional profile👤

Scopus

Strengths for the Awards✨

  • Strong Research Output & Impact 📚

    • Published multiple peer-reviewed articles in high-impact journals such as Frontiers in Pharmacology, Journal of Ethnopharmacology, and Journal of Biomolecular Structure & Dynamics.
    • Research spans diverse pharmacological applications, including colorectal cancer, anxiety treatment, ulcerative colitis, and depression, indicating a broad impact in Chinese pharmacology and molecular medicine.
    • Co-first and co-corresponding authorships in multiple papers highlight leadership in research projects.

  • Interdisciplinary Expertise 🔬

    • Skilled in network pharmacology, molecular docking, bioinformatics, and experimental validation, demonstrating a strong foundation in both computational and experimental pharmacology.
    • Expertise in cell biology, molecular biology, and animal experiments, which are critical for translational research in pharmacology.

  • Technical & Analytical Proficiency 💻

    • Proficient in essential research tools, including GraphPad, Cytoscape, Photoshop, SYBYL, and Image J, supporting advanced data analysis and visualization.

  • Recognition & Awards 🏆

    • Received the Outstanding Paper Award (2023) from the Chinese Pharmaceutical Society, a significant achievement showcasing research excellence.

  • Educational Background & Training 🎓

    • Holds a Ph.D. in Science of Chinese Pharmacology from Northwest University (2020–2024).
    • Completed a Master’s in Chinese Medicine from Shaanxi University of Chinese Medicine and a Bachelor’s in Pharmacology from Bengbu Medical University, providing a solid academic foundation.

🎓 Education

  • 📌 2020.09 – 2024.06 | Northwest University | Doctorate in Science of Chinese Pharmacology
  • 📌 2014.09 – 2017.07 | Shaanxi University of Chinese Medicine | Master’s in Chinese Medicine
  • 📌 2013.09 – 2017.07 | Bengbu Medical University | Bachelor’s in Pharmacology

💼 Experience

Shanbo Ma has been actively involved in pharmacological research, specializing in the bioactivity screening and mechanistic exploration of TCM. His work integrates network pharmacology, bioinformatics, and molecular docking techniques to elucidate drug mechanisms. He has also demonstrated proficiency in project design and team coordination, leading multiple research initiatives and collaborations.

🔬 Research Interests On Pharmacology

  •  Screening the pharmacological substance basis of traditional Chinese medicine
  •  Investigating the anti-inflammatory effects and mechanisms of TCM and its active ingredients
  •  Utilizing bioinformatics and network pharmacology to analyze drug-target interactions
  •  Exploring molecular docking and experimental validation methods for TCM efficacy

🏆 Awards

  • 🏅 Outstanding Paper Award, Chinese Pharmaceutical Society (2023)

📚 Publications

  • Elucidation of the mechanism of action of ailanthone in the treatment of colorectal cancer: integration of network pharmacology, bioinformatics analysis and experimental validation

    • Authors: Ma Shanbo, Guo Xiaodi, et al.
    • Publication Year: 2024

  • Glycyrrhizic acid treatment ameliorates anxiety-like behaviour via GLT1 and Per1/2-dependent pathways

    • Authors: Ma Shanbo, Chong Ye, et al.
    • Publication Year: 2024

  • Virtual screening-molecular docking-activity evaluation of Ailanthus altissima (Mill.) swingle bark in the treatment of ulcerative colitis

    • Authors: Ma Shanbo, Liu Lun, et al.
    • Publication Year: 2023

  • Investigating the mechanism of Sinisan formula in depression treatment: a comprehensive analysis using GEO datasets, network pharmacology, and molecular docking

    • Authors: Zheng Meiling, Yang, Shi Xiaopeng#, Ma Shanbo#
    • Publication Year: 2024

  • Network pharmacology and molecular docking to study the potential molecular mechanism of Qi Fu Yin for diabetic encephalopathy

    • Authors: Guo Xiaodi, Wang Feiyan, Ma Shanbo#, Shi Xiaopeng#
    • Publication Year: 2023

  • Investigation into the in vivo mechanism of diosmetin in patients with breast cancer and COVID-19 using bioinformatics

    • Authors: Wang Jin*, Ma Shanbo*, et al.
    • Publication Year: 2022

🔬 Skills

  •  Expertise in cell biology, molecular biology, and animal experiments
  •  Proficient in bioinformatics tools such as GraphPad, AI, Photoshop, ImageJ, Cytoscape, and SYBYL
  •  Strong ability to design projects independently and coordinate teamwork

🔚 Conclusion

Shanbo Ma is a passionate and accomplished researcher in Chinese pharmacology, making substantial contributions to understanding the therapeutic mechanisms of traditional medicines. His expertise in network pharmacology, molecular docking, and bioinformatics enhances his ability to uncover novel insights in drug discovery. With numerous publications and an award-winning research portfolio, he continues to drive advancements in the field of traditional medicine research.

Mei-Lang Kung | Pharmacology | Women Researcher Award

Published on by Forensic Scientist

Assist. Prof. Dr. Mei-Lang Kung | Pharmacology | Women Researcher Award

Senior Assistant Research Fellow | Kaohsiung Veterans General Hospital | Taiwan

Dr. Mei-Lang Kung is a distinguished researcher and academic specializing in cancer biology, gene engineering, and phytochemical pharmacology. She currently serves as a Senior Assistant Research Fellow at the Department of Medical Education and Research, Kaohsiung Veterans General Hospital, and an Assistant Professor at Shu-Zen Junior College of Medicine and Management. With a strong background in molecular biology and nanomedicine, Dr. Kung has contributed significantly to innovative research in oncology and nanomaterials for medical applications.

Profile👤

ORCID

Scopus

Strengths for the Awards✨

  • Strong Academic Background 📚

    • Dr. Mei-Lang Kung holds a Ph.D. in Biological Science from National Sun Yat-sen University (2012).
    • Her dissertation focused on cancer cell migration and epithelial-mesenchymal transition, a highly relevant area in biomedical research.

  • Extensive Research Expertise 🔬

    • Her work spans multiple interdisciplinary fields, including cancer biology, gene engineering, phytochemical pharmacology, and green nanomaterials.
    • These diverse skill sets enhance the impact of her research in translational medicine.

  • Significant Research Contributions 🏆

    • 21+ peer-reviewed publications in high-impact journals (SCI-indexed).
    • Notable research on nanomedicine and cancer treatment strategies, contributing to innovative therapeutic approaches.
    • Demonstrated leadership as a corresponding author in multiple studies, reflecting independent research capability.

  • Recognition & Awards 🥇

    • Best Poster Award (2021) from the Taiwan Urology Association.
    • National Taiwan University System Young Scholars Award (2018) for innovative research.
    • Multiple Outstanding Paper Awards at prestigious conferences (IEEE, New Advance in Medicine, etc.).
    • These accolades highlight her excellence in research and scholarly impact.

Education 🎓

Dr. Kung earned her Ph.D. in Biological Science from National Sun Yat-sen University, Kaohsiung, Taiwan, in 2012, under the guidance of Prof. Tai Ming-Hong. Her dissertation focused on the mechanisms of hepatoma-derived growth factor-mediated cell migration and epithelial-mesenchymal transition. She also holds an M.S. in Biochemistry from Kaohsiung Medical University (2002) and a B.S. in Nutrition from Chung Shan Medical University (2000).

Experience 🌟

Dr. Kung has extensive experience in academia and research. Since 2019, she has been a Senior Assistant Research Fellow at Kaohsiung Veterans General Hospital. She also holds a faculty position at Shu-Zen Junior College of Medicine and Management. Previously, she served as an Assistant Faculty member (2017-2019) and a Postdoctoral Research Associate (2012-2017) in the Chemistry Department of National Sun Yat-sen University, working under Dr. Shuchen Hsieh.

Research Interests On Pharmacology 📚

Dr. Kung’s research interests include cancer biology, gene engineering, phytochemical pharmacology, and toxicology. She is particularly focused on the development and applications of green nanomaterials for cancer treatment. Her work explores novel phytochemically derived nanoparticles and their effects on cancer cell adhesion, proliferation, and metastasis.

Awards 🏆

  • 2021: Taiwan Urology Association “Best Academic Activity Award – Best Poster Award”
  • 2018: National Taiwan University System Young Scholars Selection for Innovative Research and Development Achievements – Excellent Work Award
  • 2015: New Advance in Generation Medicine, Cancer and Stem Cell Outstanding Paper Award
  • 2013: IEEE Nanotechnology Materials and Devices Conference, Outstanding Paper Award

Publications 📰

Dr. Kung has authored numerous peer-reviewed publications in high-impact journals. Below are some of her notable works:

  1. Wang, J.-H., Chen, Y.-W., Hsieh, S., & Kung, M.-L.* (2025). “Nanosized ginger-derived phenolic zingerone obstructs cell cycle G2/M progression and initiates apoptosis in human colorectal cancer.” Environmental Toxicology. DOI:10.1002/tox.24470 (SCI; 2023 IF=4.4)
  2. Chu, L.-W., Chen, J.-Y., Chen, Y.-W., Hsieh, S., & Kung, M.-L.* (2024). “Phytoconstituent-derived zingerone nanoparticles disrupt cell adhesion and suppress cell motility in melanoma B16F10 cells.” Journal of Biotechnology. DOI:10.1016/j.jbiotec.2024.06.015
  3. Kung, M.-L., Cheng, S. M., Wang, Y.-H., et al.* (2024). “Deficiency of RNA adenosine deaminase (ADAR2) ameliorates metabolic-associated fatty liver disease via AMPK signaling pathways in male diet-induced obese mice.” Communications Biology. (SCI; 2022 IF=5.9)
  4. Kung, M.-L., Yang, T.-H., Lin, C.-C., et al.* (2024). “ADAR2 deficiency ameliorates nonalcoholic fatty liver disease and muscle atrophy through modulating serum amyloid A1.” Journal of Cachexia, Sarcopenia and Muscle. DOI:10.1002/jcsm.13460 (SCI; 2022 IF=8.9)
  5. Hu, T.-H., Wu, J.-C., Huang, S.-T., et al.* (2023). “HDGF Stimulates Liver Tumorigenesis by Enhancing Reactive Oxygen Species Generation in Mitochondria.” Journal of Biological Chemistry. (SCI; 2022 IF=4.8)

Conclusion 📚

Dr. Mei-Lang Kung has made remarkable contributions to cancer research and nanomedicine, with a strong emphasis on translating scientific discoveries into therapeutic applications. Her expertise in molecular oncology and green nanotechnology continues to impact the scientific community, making her a leader in the field of biomedical research. Through her innovative work, she strives to advance cancer treatment strategies and improve patient outcomes.

Qun Zhao | Medicine | Outstanding Scientist Award

Published on by Forensic Scientist

Prof. Qun Zhao | Medicine | Outstanding Scientist Award

The Fourth Hospital of Hebei Medical University | China

Qun Zhao is a distinguished medical professional affiliated with the Third Department of Surgery at the Fourth Hospital of Hebei Medical University. With extensive experience in surgical oncology, he has contributed significantly to the advancement of gastric and gastrointestinal cancer treatments. As a committed researcher and clinician, Dr. Zhao is an active member of multiple professional committees, driving innovation and excellence in cancer therapy.

Profile👤

ORCID

Strengths for the Awards

✅ Extensive Leadership in Oncology Research: Qun Zhao holds key positions in multiple national committees related to gastric cancer, gastrointestinal mesenchymal tumors, peritoneal tumors, tumor support therapy, and surgical nutrition. These roles highlight significant contributions to cancer research and treatment.

✅ Institutional and Professional Affiliations: Being part of the Fourth Hospital of Hebei Medical University, a reputed institution, strengthens credibility. His involvement in China’s Anti-Cancer Association further establishes his expertise in the field.

✅ Contributions to Cancer Surgery & Nutrition: Given the focus on gastric and peritoneal tumors, surgical oncology, and nutrition, Qun Zhao’s work aligns with impactful research that directly benefits patients and advances medical science.

✅ Editorial and Research Contributions: While specific journal publications, patents, or citation indices are not provided, editorial appointments and professional memberships suggest recognition by the academic community.

✅ Potential for Industry Impact: If consultancy or industry projects exist (to be detailed), they could indicate translational research, bridging academia with practical medical applications.

Education 🎓

Dr. Qun Zhao completed his medical education and specialized training in surgical oncology at renowned institutions. His academic journey has been marked by a commitment to continuous learning and specialization in gastrointestinal malignancies and surgical techniques.

Experience 🌟

Dr. Zhao holds a prominent position in the medical field, serving in various leadership roles, including the Standing Committee memberships in multiple prestigious oncology and surgical nutrition groups. His expertise extends across peritoneal tumor management, gastric cancer treatment, and gastrointestinal mesenchymal tumors. His clinical acumen and research contributions have had a significant impact on cancer treatment methodologies.

Research Interests On Medicine 🔬

Dr. Zhao’s research focuses on innovative surgical techniques, tumor nutrition, and multimodal cancer treatment strategies. His work aims to improve patient outcomes through targeted therapies and advanced surgical interventions. His ongoing projects include groundbreaking research in peritoneal metastases and gastrointestinal stromal tumors.

Awards 🏆

Dr. Zhao has been recognized for his outstanding contributions to surgical oncology and cancer research. His accolades include awards from national and international oncology societies for his pioneering work in gastric and peritoneal tumors.

Publications 📚

Dr. Zhao has authored numerous peer-reviewed articles in high-impact journals. Some of his key publications include:

  • Pioneering case: Robot-assisted remote radical distal gastrectomy for gastric cancer based on 5G communication technology
    • Authors: Honghai Guo, Yuan Tian, Jia Shi, Peigang Yang, Jiaxuan Yang, Pingan Ding, Xuefeng Zhao, Zhidong Zhang, Qun Zhao
    • Publication Year: 2024
    • DOI: 10.1016/j.isurg.2024.01.004
  • Comment on ‘Hand grip strength‐based cachexia index as a predictor of cancer cachexia and prognosis in patients with cancer’ by Xie et al.
    • Authors: Ping’an Ding, Jiaxiang Wu, Haotian Wu, Chenyu Sun, Muzi Meng, Scott Lowe, Yuan Tian, Honghai Guo, Lingjiao Meng, Qun Zhao
    • Publication Year: 2023
    • DOI: 10.1002/jcsm.13298
  • Comment on: ‘Triceps skinfold‐albumin index significantly predicts the prognosis of cancer cachexia: A multicentre cohort study’ by Yin et al.
    • Authors: Ping’an Ding, Haotian Wu, Jiaxiang Wu, Chenyu Sun, Muzi Meng, Peigang Yang, Yang Liu, Lingjiao Meng, Qun Zhao
    • Publication Year: 2023
    • DOI: 10.1002/jcsm.13304
  • Safety and efficacy of carbon nanoparticle suspension injection and indocyanine green tracer-guided lymph node dissection during robotic distal gastrectomy in patients with gastric cancer
    • Authors: Yuan Tian, Yecheng Lin, Honghai Guo, Yiyang Hu, Yong Li, Liqiao Fan, Xuefeng Zhao, Dong Wang, Bibo Tan, Qun Zhao
    • Publication Year: 2022
    • DOI: 10.1007/s00464-021-08630-8
  • Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
    • Authors: Yuan Tian, Qun Zhao, Yong Li, Liqiao Fan, Zhidong Zhang, Xuefeng Zhao, Bibo Tan, Dong Wang, Peigang Yang, Nicola Silvestris
    • Publication Year: 2021
    • DOI: 10.1155/2021/5590626

Conclusion 🥇

Dr. Qun Zhao’s dedication to oncology research and patient care continues to influence the medical community. His innovative approaches in surgery and therapeutic nutrition play a pivotal role in advancing cancer treatment. His contributions, both in research and clinical practice, underscore his commitment to improving healthcare outcomes globally.